MarketMoodz
MRK — Merck & Company, Inc.
Is MRK overbought or oversold? Here is the current MarketMoodz read.
Merck & Company, Inc. (MRK) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of July 5, 2026. The Healthcare name (Drug Manufacturers - General) last closed at $129.56. The rating moved from Overbought to Neutral on June 30, 2026 and has changed 33 times in the last 90 days.
- Public ratingNeutral (as of July 5, 2026)
- Last close$129.56
- Rating changesRating changed 33 times in the last 90 days
- Last changeMoved from Overbought to Neutral on June 30, 2026
- SectorHealthcare
- IndustryDrug Manufacturers - General
Latest MarketMoodz coverage
- Congressional Probe into Merck, AbbVie China Trials Raises Risk2026-06-30
- Gilead’s Trodelvy Clears First‑Line TNBC, Market Widens2026-06-25
- FDA Expands Merck Vaccine Label to At‑Risk Children, Teens2026-06-18
- Salesforce reportedly to buy Fin for $3.6B to beef up Agentforce AI2026-06-15
- Gilead, Merck Halt Trodelvy–Keytruda Lung Trial; Market Impact2026-06-09
See today's live rating, score and targets
Members see the live hourly rating for MRK — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.